直接凝血酶抑制剂的潜在优势。 - Suppr

Suppr

超能文献

Potential advantages of direct-acting thrombin inhibitors.

作者信息

Philippides G J, Loscalzo J

机构信息

Evans Department of Medicine, Boston University School of Medicine, Massachusetta, USA.

出版信息

Coron Artery Dis. 1996 Jul;7(7):497-507. doi: 10.1097/00019501-199607000-00003.

DOI:10.1097/00019501-199607000-00003

PMID:8913677

Abstract

摘要

相似文献

Potential advantages of direct-acting thrombin inhibitors.直接凝血酶抑制剂的潜在优势。

Coron Artery Dis. 1996 Jul;7(7):497-507. doi: 10.1097/00019501-199607000-00003.

Hirudin: initial results in acute myocardial infarction, unstable angina and angioplasty.水蛭素：急性心肌梗死、不稳定型心绞痛及血管成形术的初步研究结果

J Am Coll Cardiol. 1995 Jun;25(7 Suppl):30S-37S. doi: 10.1016/0735-1097(95)00104-c.

Direct thrombin inhibitors for non-ST-segment elevation acute coronary syndromes: what, when, and where?用于非ST段抬高型急性冠脉综合征的直接凝血酶抑制剂：是什么、何时使用以及在何处使用？

Am Heart J. 2003 Oct;146(4 Suppl):S23-30. doi: 10.1016/j.ahj.2003.09.005.

[Direct thrombin antagonists].[直接凝血酶拮抗剂]

Herz. 2001 Apr;26 Suppl 1:46-52. doi: 10.1007/pl00014032.

Pharmacological properties of hirudin and its derivatives. Potential clinical advantages over heparin.水蛭素及其衍生物的药理特性。相对于肝素的潜在临床优势。

Drugs Aging. 1996 Mar;8(3):171-82. doi: 10.2165/00002512-199608030-00003.

Advances in antithrombotic therapy: novel agents.

Thromb Haemost. 1995 Jul;74(1):565-71.

Bivalirudin for percutaneous coronary intervention and in acute coronary syndromes.比伐卢定用于经皮冠状动脉介入治疗及急性冠状动脉综合征。

Curr Cardiol Rep. 2001 Sep;3(5):348-54. doi: 10.1007/s11886-001-0050-9.

Hirudin and hirudin analogues as new anticoagulant agents.水蛭素及水蛭素类似物作为新型抗凝剂

Curr Opin Hematol. 1995 Sep;2(5):380-5. doi: 10.1097/00062752-199502050-00009.

The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes.肝素、低分子量肝素、五糖及水蛭素在静脉血栓栓塞症和急性冠脉综合征治疗中的现状与未来

Semin Vasc Med. 2003 May;3(2):139-46. doi: 10.1055/s-2003-40672.

Bivalirudin: a review of its potential place in the management of acute coronary syndromes.比伐卢定：对其在急性冠脉综合征管理中潜在地位的综述

Drugs. 2002;62(5):841-70. doi: 10.2165/00003495-200262050-00008.

引用本文的文献

Design, Synthesis, and Evaluation of New Hybrid Derivatives of 5,6-Dihydro-4-pyrrolo[3,2,1-]quinolin-2(1)-one as Potential Dual Inhibitors of Blood Coagulation Factors Xa and XIa.新型 5,6-二氢-4-吡咯并[3,2,1-]喹啉-2(1H)-酮类杂合衍生物的设计、合成与评价作为潜在的凝血因子 Xa 和 XIa 的双重抑制剂。

Molecules. 2024 Jan 11;29(2):373. doi: 10.3390/molecules29020373.

Evaluation of novel factor Xa inhibitors from Oxya chinensis sinuosa with anti-platelet aggregation activity.评价中华稻蝗来源的新型 Xa 因子抑制剂的抗血小板聚集活性。

Sci Rep. 2017 Aug 11;7(1):7934. doi: 10.1038/s41598-017-08330-1.

A Novel Direct Factor Xa Inhibitory Peptide with Anti-Platelet Aggregation Activity from Agkistrodon acutus Venom Hydrolysates.一种从尖吻蝮蛇毒水解物中提取的具有抗血小板聚集活性的新型直接凝血因子Xa抑制肽。

Sci Rep. 2015 Jun 2;5:10846. doi: 10.1038/srep10846.

Role of thrombin in CNS damage associated with intracerebral haemorrhage: opportunity for pharmacological intervention?凝血酶在与脑出血相关的中枢神经系统损伤中的作用：药物干预的机会？

CNS Drugs. 2002;16(8):509-16. doi: 10.2165/00023210-200216080-00001.

Antithrombotic effect of LB-30057 (CI-1028), a new synthetic thrombin inhibitor, in a rabbit model of thrombosis: comparison with inogatran.新型合成凝血酶抑制剂LB-30057（CI-1028）在兔血栓形成模型中的抗血栓作用：与伊诺加群的比较

J Thromb Thrombolysis. 2001 Feb;11(1):19-31. doi: 10.1023/a:1008900109285.

Effects of Intravenous Enoxaparin and Intravenous Inogatran in an Electrolytic Injury Model of Venous Thrombosis in the Dog.静脉注射依诺肝素和静脉注射伊诺加群在犬静脉血栓形成电解损伤模型中的作用

J Thromb Thrombolysis. 1998 Nov;6(3):199-206. doi: 10.1023/A:1008806312396.

Antithrombotic effects of BCH 2763, a new direct thrombin inhibitor, in a canine model of venous thrombosis.

J Thromb Thrombolysis. 1999 Jun;7(3):301-6. doi: 10.1023/a:1008987211850.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验